Core Viewpoint - Shenzhen Hujia Technology (Group) Co., Ltd. has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with its brand HBN being a leading domestic skincare brand advocating the "early C, late A" skincare concept, and spending over 1 billion yuan annually on promotions [1][4]. Financial Performance - The company's revenue for the years 2023, 2024, and the first three quarters of 2025 were 1.948 billion yuan, 2.083 billion yuan, and 1.514 billion yuan respectively, with net profits of 39 million yuan, 129 million yuan, and 145 million yuan, and gross profit margins of 76.6%, 73.4%, and 75.3% [4]. - Revenue primarily comes from "improvement-type skincare products" and "stabilizing-type skincare products," with the former accounting for 78.3% to 81.8% of total revenue during the reporting period [4]. Business Model - The company heavily relies on a single brand, HBN, with its core growth driven by the market performance of concepts like "early C, late A" [4]. - Online sales channels accounted for 98.6%, 98.7%, and 95.1% of total sales during the reporting periods, indicating a strong dependence on e-commerce [4]. Inventory Management - The company's inventory at the end of each reporting period was 140 million yuan, 178 million yuan, and 180 million yuan, with inventory turnover days increasing from 113 days to 130 days, showing a significant upward trend [4]. Marketing and Promotion - Sales and distribution expenses were 1.268 billion yuan, 1.238 billion yuan, and 871 million yuan, representing 65.1%, 59.4%, and 57.6% of total revenue during the respective periods [7]. - The company emphasizes the need for effective brand, market, and marketing strategies to attract and retain consumers, leveraging social media and KOLs for promotion [7]. Shareholding Structure - The founder, Yao Zhenan, and his wife control 76.19% of the voting rights in the company, with Yao holding 35.08% directly and an additional 19.51% through proxy arrangements [9][11]. - The company declared a cash dividend of 100 million yuan prior to its listing application, with nearly 50 million yuan expected to benefit the controlling couple [11] Use of Proceeds - The funds raised from the listing will be used for R&D and product innovation, enhancing production capacity, improving office environments, boosting digital operations, investing in brand and market promotion, and general corporate purposes [12].

Core Viewpoint - HBN, a domestic skincare brand, has submitted its IPO application to the Hong Kong Stock Exchange, aiming to expand its market presence and enhance product innovation [1]. Financial Performance - HBN's revenue for 2023, 2024, and the first nine months of 2025 is projected to be CNY 19.48 billion, CNY 20.83 billion, and CNY 15.14 billion, respectively, with a year-on-year growth of 6.9% in 2024 and 10.2% in the first nine months of 2025 [1][2]. - Net profit for the same periods is expected to be CNY 0.39 billion, CNY 1.29 billion, and CNY 1.45 billion, showing a significant increase of 232.5% in 2024 and 190.3% in the first nine months of 2025, with net profit margin rising from 1.9% to 9.6% [1][2]. Product Lines - HBN offers a range of skincare products, including anti-aging, brightening, repairing, and basic skincare lines, with a total of 36 SKUs available by September 30, 2025 [1]. - The core business of improvement-type skincare products generated revenues of CNY 15.94 billion, CNY 16.31 billion, and CNY 11.90 billion for the years 2023, 2024, and the first nine months of 2025, with gross margins of 76.4%, 72.4%, and 74.5%, respectively [2][3]. Sales Channels - Online sales remain the primary revenue source, accounting for over 95% of total revenue from 2023 to the first nine months of 2025, with revenues of CNY 19.20 billion, CNY 20.34 billion, and CNY 14.39 billion [3]. - Offline sales are emerging as a new growth area, with revenues increasing from CNY 0.28 billion in 2023 to CNY 0.75 billion in the first nine months of 2025, raising its share from 1.4% to 4.9% [3]. Marketing and R&D Expenditure - Sales and distribution expenses for 2023 and 2024 were CNY 12.67 billion and CNY 12.38 billion, representing 65.1% and 59.4% of total revenue, respectively [4]. - R&D expenditures have decreased, with amounts of CNY 0.66 billion, CNY 0.58 billion, and CNY 0.40 billion for 2023, 2024, and the first nine months of 2025, accounting for 3.4%, 2.8%, and 2.6% of total revenue [4]. - The IPO proceeds will be directed towards R&D, product innovation, capacity upgrades, digital operations, and multi-channel expansion [4].